Cargando…
Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome
Visual evoked potentials (VEP) are changes in potentials that arise in the central nervous system. In the interpretation of the VEP test results, it is assumed that the elongation of the latency time is caused by the demyelination of the nerve fibers, and the axon damage is responsible for the decre...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467284/ https://www.ncbi.nlm.nih.gov/pubmed/34575305 http://dx.doi.org/10.3390/jcm10184196 |
_version_ | 1784573358020493312 |
---|---|
author | Dziadkowiak, Edyta Sebastian, Agata Wieczorek, Malgorzata Pokryszko-Dragan, Anna Madej, Marta Waliszewska-Prosół, Marta Budrewicz, Sławomir Wiland, Piotr Ejma, Maria |
author_facet | Dziadkowiak, Edyta Sebastian, Agata Wieczorek, Malgorzata Pokryszko-Dragan, Anna Madej, Marta Waliszewska-Prosół, Marta Budrewicz, Sławomir Wiland, Piotr Ejma, Maria |
author_sort | Dziadkowiak, Edyta |
collection | PubMed |
description | Visual evoked potentials (VEP) are changes in potentials that arise in the central nervous system. In the interpretation of the VEP test results, it is assumed that the elongation of the latency time is caused by the demyelination of the nerve fibers, and the axon damage is responsible for the decrease in the amplitude. The observed VEP deviations are not specific for specific diseases, but indicate disturbances in visual conductivity. VEP may play a diagnostic role in the early detection of visual involvement. The aim of the study was the functioning of visual pathway assessment on the basis of visual evoked potentials (VEP) examination, in patients with primary Sjögren’s Syndrome (pSS), without focal symptoms of central nervous system disorder. The effect of disease activity, as assessed by clinical parameters and antibody levels (anti-Ro52, SSA, and SSB), on the central nervous system was also evaluated. Thirty-two consecutive patient with pSS (31 females, 1 male) were included in the study. VEP was performed at baseline, and after 6 (T6) years. Their results were compared longitudinally between the baseline and T6, depending on the duration of the disease and treatment. The immunological activity of pSS was also analyzed. The group of patients showed a significant prolongation of the P100 implicit time (105.5 ± 5.1 vs. 100.6 ± 3.9; p = 0.000) and a significant higher the P100-N145 amplitude (12.3 ± 4.1 vs. 9.4 ± 3.0; p = 0.000). Abnormalities in electrophysiological parameters of VEP at baseline correlated with presentation of anti-Ro52 antibodies and aching joints. At baseline, the P100 implicit time was shorter for the patients with pSS than for those at T6 (105.50 ± 5.1 vs. 109.37 ± 5.67; p = 0.002). pSS patients without CNS involvement presented with dysfunction of visual pathway, as revealed by VEP abnormalities. Relationships were found between VEP parameters and with present of anti-Ro52 antibodies and aching joints. VEP may be a useful method for assessment and monitoring of subclinical visual deficit in the course of pSS. |
format | Online Article Text |
id | pubmed-8467284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84672842021-09-27 Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome Dziadkowiak, Edyta Sebastian, Agata Wieczorek, Malgorzata Pokryszko-Dragan, Anna Madej, Marta Waliszewska-Prosół, Marta Budrewicz, Sławomir Wiland, Piotr Ejma, Maria J Clin Med Article Visual evoked potentials (VEP) are changes in potentials that arise in the central nervous system. In the interpretation of the VEP test results, it is assumed that the elongation of the latency time is caused by the demyelination of the nerve fibers, and the axon damage is responsible for the decrease in the amplitude. The observed VEP deviations are not specific for specific diseases, but indicate disturbances in visual conductivity. VEP may play a diagnostic role in the early detection of visual involvement. The aim of the study was the functioning of visual pathway assessment on the basis of visual evoked potentials (VEP) examination, in patients with primary Sjögren’s Syndrome (pSS), without focal symptoms of central nervous system disorder. The effect of disease activity, as assessed by clinical parameters and antibody levels (anti-Ro52, SSA, and SSB), on the central nervous system was also evaluated. Thirty-two consecutive patient with pSS (31 females, 1 male) were included in the study. VEP was performed at baseline, and after 6 (T6) years. Their results were compared longitudinally between the baseline and T6, depending on the duration of the disease and treatment. The immunological activity of pSS was also analyzed. The group of patients showed a significant prolongation of the P100 implicit time (105.5 ± 5.1 vs. 100.6 ± 3.9; p = 0.000) and a significant higher the P100-N145 amplitude (12.3 ± 4.1 vs. 9.4 ± 3.0; p = 0.000). Abnormalities in electrophysiological parameters of VEP at baseline correlated with presentation of anti-Ro52 antibodies and aching joints. At baseline, the P100 implicit time was shorter for the patients with pSS than for those at T6 (105.50 ± 5.1 vs. 109.37 ± 5.67; p = 0.002). pSS patients without CNS involvement presented with dysfunction of visual pathway, as revealed by VEP abnormalities. Relationships were found between VEP parameters and with present of anti-Ro52 antibodies and aching joints. VEP may be a useful method for assessment and monitoring of subclinical visual deficit in the course of pSS. MDPI 2021-09-16 /pmc/articles/PMC8467284/ /pubmed/34575305 http://dx.doi.org/10.3390/jcm10184196 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dziadkowiak, Edyta Sebastian, Agata Wieczorek, Malgorzata Pokryszko-Dragan, Anna Madej, Marta Waliszewska-Prosół, Marta Budrewicz, Sławomir Wiland, Piotr Ejma, Maria Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome |
title | Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome |
title_full | Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome |
title_fullStr | Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome |
title_full_unstemmed | Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome |
title_short | Visual Evoked Potentials as Potential Biomarkers of Visual Function in Patients with Primary Sjögren’s Syndrome |
title_sort | visual evoked potentials as potential biomarkers of visual function in patients with primary sjögren’s syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467284/ https://www.ncbi.nlm.nih.gov/pubmed/34575305 http://dx.doi.org/10.3390/jcm10184196 |
work_keys_str_mv | AT dziadkowiakedyta visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome AT sebastianagata visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome AT wieczorekmalgorzata visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome AT pokryszkodragananna visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome AT madejmarta visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome AT waliszewskaprosołmarta visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome AT budrewiczsławomir visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome AT wilandpiotr visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome AT ejmamaria visualevokedpotentialsaspotentialbiomarkersofvisualfunctioninpatientswithprimarysjogrenssyndrome |